Vaxcyte
PCVX
106 hedge funds and large institutions have $1.12B invested in Vaxcyte in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 47 increasing their positions, 20 reducing their positions, and 5 closing their positions.
133,825% more call options, than puts
Call options by funds: $5.36M | Put options by funds: $4K
380% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 5
135% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 20
20% more funds holding
Funds holding: 88 → 106 (+18)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
0.33% less ownership
Funds ownership: 88.54% → 88.21% (-0.33%)
7% less capital invested
Capital invested by funds: $1.2B → $1.12B (-$84.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$19.1M |
| 2 |
State Street
Boston,
Massachusetts
|
+$10.9M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
+$10.8M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$10.6M |
| 5 |
BlackRock
New York
|
+$8.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$31.5M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$23.5M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$12.1M |
| 4 |
TGA
TPG GP A
Fort Worth,
Texas
|
-$8.97M |
| 5 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
-$6.46M |
PCVX Hedge Fund Activity: Q2 2022 in Review
106 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q2 2022, worth a combined $1.12B — down 7% from $1.2B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new PCVX positions and 5 closed out — a net gain of 19 holders — while 47 added to existing stakes and 20 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $19.1M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $31.5M sold.
- 106 institutional investors held Vaxcyte (PCVX) as of Q2 2022, up from 88 in Q1 2022.
- Funds reported $1.12B of Vaxcyte stock for Q2 2022, down 7% quarter-over-quarter.
- 24 funds opened new Vaxcyte positions in Q2 2022 and 5 closed out, a net change of +19 holders.
- The largest Vaxcyte buyer in Q2 2022 was Novo Holdings A/S, an estimated $19.1M added.
- The largest Vaxcyte seller in Q2 2022 was EcoR1 Capital, an estimated $31.5M sold.
Based on aggregated 13F filings for Q2 2022.